| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 606 | 889 | 323 | 1,127 | 1,329 |
| Sales Growth | -31.82% | +175.63% | -71.38% | -15.20% | +69.57% |
| Net Income | 407 | -1,386 | -1,301 | -1,503 | -2,644 |
| Net Income Growth | +129.40% | -6.52% | +13.42% | +43.16% | -2.66% |
Pharmacielo Ltd (PCLO.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Fiscal Year End Date: 12/31